2-Amino-5-[[1-(carboxymethylamino)-3-[2-(4-chlorophenyl)-2-oxoethyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid | 33812-53-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-5-[[1-(carboxymethylamino)-3-[2-(4-chlorophenyl)-2-oxoethyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• CAS: 33812-53-2
• 化学式: C₁₈H₂₂ClN₃O₇S
• 分子量: 459.9
• InChiKey: GWJGEAYYIHDOFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  201
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Conjugates of leukotrienes with proteins
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0179959A1

  公开（公告）日：1986-05-07

  Leukotrienes B4, C4, D4 and E4 are conjugated with various proteins, viz. Bovine Serum Albumin, Hemocyanin from Giant Keyhole Limpets, human serum albumin, tetanus antigen, diphtheriae toxoid and CRM 197 using 1,5-difluoro-2,4-dinitrobenzene or 6-N-maleimido(C2-8 alkanoic acid)-chloride as coupling agent. These conjugates are useful as reagents in a newly developed immunoassay for leukotrienes, as well as having potential utility as chemical immunotherapeutic agents in the treatment of various allergic and chronic inflammatory diseases of the skin, lung, and airways, including asthma, allergic rhinitis, rheumatoid arthritis, and skin diseases such as psoriasis and eczema. They may be made into pharmaceutical compositions. Certain novel intermediate compounds are also provided.

  白三烯 B4、C4、D4 和 E4 以 1,5-二氟-2,4-二硝基苯或 6-N-马来酰亚胺基（C2-8 烷酸）-盐酸盐为偶联剂，与各种蛋白质（即牛血清白蛋白、巨匙孔蛙的血蓝蛋白、人血清白蛋白、破伤风抗原、白喉类毒素和 CRM 197）共轭。 这些共轭物可用作新开发的白三烯免疫测定试剂，也可用作化学免疫治疗剂，用于治疗皮肤、肺部和呼吸道的各种过敏性和慢性炎症性疾病，包括哮喘、过敏性鼻炎、类风湿性关节炎以及牛皮癣和湿疹等皮肤病。它们可以制成药物组合物。 还提供了某些新型中间体化合物。
• Liposomes for protection against toxic compounds
  申请人：Awasthi Sanjay

  公开号：US20050123594A1

  公开（公告）日：2005-06-09

  Generally, and in one form, the present invention is a method of method of preparing a proteoliposome comprising the step of contacting a liposome with an effective portion of RLIP76 to create a proteoliposome. In another form, the present invention is a proteoliposomal composition comprising a liposome and an effective portion of RLIP76. In yet another form, the present invention is a kit for reducing the concentration of toxic compounds and their by-products comprising an effective dose of a proteoliposome, wherein the proteoliposome is a liposome and an effective portion of RLIP76 and an instructional pamphlet. Applications of the present invention include the protection and treatment of mammals and the environment against the accumulation of toxic compounds. The present invention prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.

  一般来说，在一种形式中，本发明是一种制备蛋白脂质体的方法，包括将脂质体与有效部分的RLIP76接触以产生蛋白脂质体的步骤。在另一种形式中，本发明是一种蛋白脂质体组合物，包括脂质体和有效部分的 RLIP76。在另一种形式中，本发明是一种用于降低有毒化合物及其副产物浓度的试剂盒，包括有效剂量的蛋白脂质体，其中蛋白脂质体是脂质体和有效部分的 RLIP76 以及说明书。本发明的应用包括保护和治疗哺乳动物和环境，防止有毒化合物的积累。本发明可防止一种或多种有毒化合物的积累，降低有毒化合物的浓度，并防止进一步受到一种或多种有毒化合物的污染。
• LIPOSOMES FOR PROTECTION AGAINST TOXIC COMPOUNDS
  申请人：Awasthi Sanjay

  公开号：US20080279919A1

  公开（公告）日：2008-11-13

  Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.
• Protection against and treatment of ionizing radiation
  申请人：Awasthi Sanjay

  公开号：US20100124566A1

  公开（公告）日：2010-05-20

  Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds. In addition, RalBP1 is effective for the protection and treatment of mammals against the effects of ionizing radiation.
• Protection Against and Treatment of Ionizing Radiation
  申请人：Awasthi Sanjay

  公开号：US20120226090A1

  公开（公告）日：2012-09-06

  Methods of preparing a proteoliposorne comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposorne. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds. In addition, RalBP1 is effective for the protection and treatment of mammals against the effects of ionizing radiation.